Navigation Links
IDEV Announces Full Canadian Regulatory Approval for SUPERA VERITASĀ®
Date:4/14/2011

WEBSTER, Texas, April 14, 2011 /PRNewswire/ -- The Medical Devices Bureau of Health Canada has granted regulatory approval for the SUPERA VERITAS stent system for use in biliary and peripheral procedures.  IDEV's unique stent was previously available on a limited basis only, through the Special Access Program.

Christopher Owens, President and CEO of IDEV, commented, "With the full regulatory approval that has been granted we can immediately launch SUPERA VERITAS throughout Canada.  Based on early work with key physicians we anticipate rapid acceptance of our technology, and are pleased to offer this treatment option to physicians and their patients."

The approval clears the way for clinicians to utilize the SUPERA stent for patients with peripheral vascular disease (PVD) as well as those diagnosed with biliary strictures resulting from malignant neoplasms.  The proven mechanical characteristics of the SUPERA stent, including unmatched radial strength and fracture resistance, may result in improved clinical outcomes for these patients.

"Gaining full approval in Canada for SUPERA VERITAS is a significant development for the market," stated Vincent Oliva, M.D., Chief of Interventional Radiology at Centre Hospitalier de L'Universite de Montreal (CHUM).  "Based upon my experience, the highly differentiated features of the device, including its high radial strength and fracture resistance, and the clinical data presented showing exceptional outcomes, provide clinicians with a new and exciting option for treating PVD."

About IDEV Technologies, IncorporatedIDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology.  IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.  For more information please visit

SOURCE IDEV Technologies, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Trial... -- MONT-SAINT-GUIBERT, Belgium, November 17, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... 2010 In response to an expressed need by ... facilitate the sharing and exchanging of data among PMP ... will be developing an interconnected communications hub for state ... nine months, will be made accessible to the states ...
Cached Medicine Technology:Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 2Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 3Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 4Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 5Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 6Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 7Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 8Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 9Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 10Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 11Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients 12NABP Developing System to Link Prescription Monitoring Programs Across States to Facilitate Data Exchange 2
(Date:4/23/2014)... health benefits of probiotics, antioxidants and other nutritional compounds, ... chemical industry is getting in on the action. But ... so the industry is responding with clinical research to ... in Chemical & Engineering News (C&EN), the ... Melody M. Bomgardner, a senior editor at C&EN, writes ...
(Date:4/23/2014)... concerned about an increase in adolescents, marijuana use following ... of relief. According to a new study at Rhode ... from states with and without medical marijuana laws, legalizing ... adolescents. The study is published online in advance of ... , "Any time a state considers legalizing medical ...
(Date:4/23/2014)... the bottom of Alzheimer,s disease has been a ... controversies. In the latest crook in the research ... the interaction between proteins associated with the disease. ... ACS Chemical Neuroscience , could have important implications ... Krzysztof Nieznanski and colleagues explain that for years, ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... The International Communication Association will hold its 64th ... theme of the 2014 conference will explore what ... digital society. , Featuring over 2,300 academic papers ... scholars representing over 40 countries, the ICA conference ... the world. This year,s conference features sessions that ...
Breaking Medicine News(10 mins):Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... content talking to an imaginary friend rather than a real one ... such a pal can have a positive effect on children. ... in London also insists that imaginary friends are not a sign ... his or her age group, but a sign that your child ...
... drugs may give a man's performance in bed a boost, ... or their relationships . ,A survey of ... have poorer esteem, a weaker sense of masculinity and lower ... dysfunction (ED), including half who had tried drug treatment, and ...
... hope revived for women who feel less than that, after ... claim that stem cells found in the ubiquitous tummy fat ... this is so, it would be killing two birds with ... ,Christened Celution, the procedure involves injecting a 'supercharged' fat ...
... Dr. Endress and his colleagues found that the sizes ... buzz-pollinating bees . The male floral structures, anthers, release ... ,Unlike moths and butterflies that are often brilliantly ... flowers and the fruits they produce have brilliant colors ...
... increases a person's risk of colon cancer by 23 percent ... by a team of researchers from the University of Michigan ... Institute of Oncology in Spain, the CHS National Israeli Cancer ... including Stephen Gruber and Gad Rennert. ,As part ...
... treatments using their knowledge about an obesity drug, orlistat (Xenical ... the laboratory . ,The drug binds and interacts ... protein's function and causes cell death. ,The study ... and W. Todd Lowther at Wake Forest University School of ...
Cached Medicine News:Health News:Stem Cells In Belly Fat To Enhance Or Reconstruct Breasts 2Health News:Size and Position of Floral Anther Plays a Vital Role in Pollination 2Health News:Size and Position of Floral Anther Plays a Vital Role in Pollination 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: